ATE252373T1 - Feste verabreichungssysteme zur gesteuerten freisetzung von darin eingebauten molekülen sowie verfahren zu deren herstellung - Google Patents

Feste verabreichungssysteme zur gesteuerten freisetzung von darin eingebauten molekülen sowie verfahren zu deren herstellung

Info

Publication number
ATE252373T1
ATE252373T1 AT95927856T AT95927856T ATE252373T1 AT E252373 T1 ATE252373 T1 AT E252373T1 AT 95927856 T AT95927856 T AT 95927856T AT 95927856 T AT95927856 T AT 95927856T AT E252373 T1 ATE252373 T1 AT E252373T1
Authority
AT
Austria
Prior art keywords
production
controlled release
administration systems
molecules incorporated
solid administration
Prior art date
Application number
AT95927856T
Other languages
English (en)
Inventor
Bruce Joseph Roser
Camilo Colaco
Mohamed Abdel Zahra Jerrow
Julian Alexander Landcli Blair
Jaap Kampinga
James Lewis Wardell
John Alistair Duffy
Original Assignee
Elan Drug Delivery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26305403&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE252373(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB9415810A external-priority patent/GB9415810D0/en
Priority claimed from US08/349,029 external-priority patent/US6290991B1/en
Application filed by Elan Drug Delivery Ltd filed Critical Elan Drug Delivery Ltd
Application granted granted Critical
Publication of ATE252373T1 publication Critical patent/ATE252373T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Detergent Compositions (AREA)
  • Lubricants (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT95927856T 1994-08-04 1995-08-04 Feste verabreichungssysteme zur gesteuerten freisetzung von darin eingebauten molekülen sowie verfahren zu deren herstellung ATE252373T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9415810A GB9415810D0 (en) 1994-08-04 1994-08-04 Composition
US08/349,029 US6290991B1 (en) 1994-12-02 1994-12-02 Solid dose delivery vehicle and methods of making same
PCT/GB1995/001861 WO1996003978A1 (en) 1994-08-04 1995-08-04 Solid delivery systems for controlled release of molecules incorporated therein and methods of making same

Publications (1)

Publication Number Publication Date
ATE252373T1 true ATE252373T1 (de) 2003-11-15

Family

ID=26305403

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95927856T ATE252373T1 (de) 1994-08-04 1995-08-04 Feste verabreichungssysteme zur gesteuerten freisetzung von darin eingebauten molekülen sowie verfahren zu deren herstellung

Country Status (20)

Country Link
EP (4) EP0773781B1 (de)
JP (2) JPH10503769A (de)
CN (1) CN1152670C (de)
AT (1) ATE252373T1 (de)
BG (1) BG101278A (de)
CA (1) CA2197982C (de)
CZ (1) CZ297431B6 (de)
DE (1) DE69531992T2 (de)
DK (1) DK0773781T3 (de)
EE (1) EE03593B1 (de)
ES (1) ES2208687T3 (de)
FI (1) FI970867A7 (de)
HU (1) HUT77777A (de)
MX (1) MX9701394A (de)
NO (1) NO326966B1 (de)
NZ (1) NZ290896A (de)
PL (1) PL184068B1 (de)
PT (1) PT773781E (de)
SK (1) SK283026B6 (de)
WO (1) WO1996003978A1 (de)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0679088T3 (da) 1992-09-29 2002-10-28 Inhale Therapeutic Syst Pulmonal levering af aktive fragmenter af parathyreoideaea hormon
DE69535897D1 (de) 1994-03-07 2009-01-22 Nektar Therapeutics Verfahren und Zusammensetzung für die pulmonale Darreichung von Insulin
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
CZ88697A3 (en) 1994-09-22 1997-09-17 Quadrant Holdings Cambridge Composition used for re-hydration and nourishment in the course of athletic outputs and processes for preparing thereof
US6258341B1 (en) * 1995-04-14 2001-07-10 Inhale Therapeutic Systems, Inc. Stable glassy state powder formulations
US6309671B1 (en) 1995-04-14 2001-10-30 Inhale Therapeutic Systems Stable glassy state powder formulations
GB9508691D0 (en) * 1995-04-28 1995-06-14 Pafra Ltd Stable compositions
GB9606188D0 (en) * 1996-03-23 1996-05-29 Danbiosyst Uk Pollysaccharide microspheres for the pulmonary delivery of drugs
ZA9711732B (en) * 1996-12-31 1998-12-28 Quadrant Holdings Cambridge Methods and compositions for improvement bioavailability of bioactive agents for mucosal delivery
GB9705588D0 (en) * 1997-03-18 1997-05-07 Anglia Research Foundation Stable particle in liquid formulations
WO1999001463A2 (en) * 1997-07-03 1999-01-14 Quadrant Holdings Cambridge Limited Modified glycosides, compositions comprised thereof and methods of use thereof
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6946117B1 (en) 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
US6352722B1 (en) 1997-12-23 2002-03-05 Quadrant Holdings Cambridge Limited Derivatized carbohydrates, compositions comprised thereof and methods of use thereof
AU2484399A (en) * 1998-01-30 1999-08-16 Scios Inc. Controlled release delivery of peptide or protein
US6455096B1 (en) 1998-04-28 2002-09-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Hard candy with a relatively-high moisture and hardness, and process of the same
RU2165264C2 (ru) * 1998-07-10 2001-04-20 Бичурина Маина Александровна Фармацевтическая композиция для лечения герпеса
AU5751799A (en) * 1998-09-09 2000-03-27 Quadrant Holdings Cambridge Limited Filamentous amorphous carbohydrate compositions and therapeutic delivery vehicles comprising them
AU3957400A (en) 1999-04-16 2000-11-02 Novo Nordisk A/S Dry, mouldable drug formulation
GB9916316D0 (en) 1999-07-12 1999-09-15 Quadrant Holdings Cambridge Dry powder compositions
US8632785B2 (en) 2000-02-08 2014-01-21 Allergan, Inc. Clostridial toxin pharmaceutical composition containing a gelatin fragment
US7780967B2 (en) 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
ES2237551T3 (es) * 2000-02-08 2005-08-01 Allergan, Inc. Composiciones farmaceuticas que contienen toxina botulinica.
JP3419729B2 (ja) * 2000-03-16 2003-06-23 株式会社ファンケル 錠剤およびその製造方法
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
PT1280520E (pt) 2000-05-10 2014-12-16 Novartis Ag Pós à base de fosfolípidos para administração de fármacos
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US7575761B2 (en) 2000-06-30 2009-08-18 Novartis Pharma Ag Spray drying process control of drying kinetics
GB0017999D0 (en) * 2000-07-21 2000-09-13 Smithkline Beecham Biolog Novel device
GB0020616D0 (en) * 2000-08-21 2000-10-11 Quadrant Holdings Cambridge Particulates
EP1449523A1 (de) * 2000-10-13 2004-08-25 Cambridge Biostability Ltd Zusammensetzung und Verfahren für injizierbare Flüssigkeiten
CA2427381A1 (en) 2000-10-26 2002-11-28 Alza Corporation Transdermal drug delivery devices having coated microprotrusions
US6623762B2 (en) * 2001-02-16 2003-09-23 Cambridge Biostability Ltd. Composition and method for controlled release injections
NZ529029A (en) * 2001-04-20 2005-07-29 Alza Corp Microprojection array having a beneficial agent containing coating
GB0124710D0 (en) * 2001-10-15 2001-12-05 Quadrant Healthcare Uk Ltd Therapeutic composition
EP1992335A1 (de) 2001-11-01 2008-11-19 Nektar Therapeutics Sprühtrocknungsverfahren und Zusammensetzungen dafür
DE10157124A1 (de) * 2001-11-21 2003-05-28 Lohmann Therapie Syst Lts Mikrofaserhaltige Vorrichtung zur kontrollierten Freisetzung von Stoffen
US8454997B2 (en) 2001-12-18 2013-06-04 Novo Nordisk A/S Solid dose micro implant
TWI324518B (en) 2001-12-19 2010-05-11 Nektar Therapeutics Pulmonary delivery of aminoglycosides
GB0201736D0 (en) * 2002-01-25 2002-03-13 Glaxo Group Ltd DNA dosage forms
ATE357219T1 (de) * 2002-01-25 2007-04-15 Glaxo Group Ltd Darreichungsformen für dns
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
GB0210771D0 (en) * 2002-05-10 2002-06-19 Univ London Pharmacy Derivatised particulate inhalation carriers
EP1428526A1 (de) * 2002-12-13 2004-06-16 Rijksuniversiteit Groningen Zusammensetzung zur schnellen Freisetzung von lipophilen Stoffen
CA2530531A1 (en) 2003-06-30 2005-01-20 Alza Corporation Formulations for coated microprojections containing non-volatile counterions
EP1643974A1 (de) * 2003-07-11 2006-04-12 Glaxo Group Limited Pharmazeutische zusammensetzungen enthaltend einen zuckerester
GB0327727D0 (en) * 2003-11-28 2003-12-31 Quadrant Drug Delivery Ltd Viral microparticles
US7884085B2 (en) 2004-05-12 2011-02-08 Baxter International Inc. Delivery of AS-oligonucleotide microspheres to induce dendritic cell tolerance for the treatment of autoimmune type 1 diabetes
EP1765294B1 (de) 2004-05-12 2008-09-24 Baxter International Inc. Nukleinsäure-mikrokügelchen, ihre herstellung und abgabe
MXPA06013168A (es) 2004-05-13 2007-05-15 Johnson & Johnson Aparato y metodo para el suministro transdermico de agentes de la hormona paratiroidea.
JP4547994B2 (ja) 2004-06-02 2010-09-22 救急薬品工業株式会社 塊状物質含有積層フィルム状の可食性口腔内投与剤の製造方法および塊状物質含有積層フィルム状の可食性口腔内投与剤
TW200621310A (en) * 2004-11-10 2006-07-01 Univ Groningen A process for preparing formulations of lypophilic active substances by spray freeze drying
US20070009564A1 (en) 2005-06-22 2007-01-11 Mcclain James B Drug/polymer composite materials and methods of making the same
EP2324850A1 (de) 2005-10-04 2011-05-25 Alk-Abelló A/S Feste Impfstofformulierung
JP2009522288A (ja) 2005-12-28 2009-06-11 アルザ コーポレイション 安定な治療剤形
EP1832281A1 (de) 2006-03-10 2007-09-12 Abbott GmbH & Co. KG Verfahren zur Herstellung einer Feststoffdispersion eines aktiven Wirkstoffes
US7815603B2 (en) 2006-05-17 2010-10-19 Alcon Research, Ltd. Ophthalmic injection method
US7887521B2 (en) 2006-05-17 2011-02-15 Alcon Research, Ltd. Ophthalmic injection system
US20070270750A1 (en) 2006-05-17 2007-11-22 Alcon, Inc. Drug delivery device
US7674243B2 (en) 2006-05-17 2010-03-09 Alcon Inc. Ophthalmic injection device using piezoelectric array
US7811252B2 (en) 2006-05-17 2010-10-12 Alcon Research, Ltd. Dosage control device
US7862540B2 (en) 2006-05-17 2011-01-04 Alcon Research, Ltd. Ophthalmic injection device using shape memory alloy
US20080281292A1 (en) 2006-10-16 2008-11-13 Hickingbotham Dyson W Retractable Injection Port
US9022970B2 (en) 2006-10-16 2015-05-05 Alcon Research, Ltd. Ophthalmic injection device including dosage control device
PT2101731T (pt) * 2006-11-21 2018-04-18 Jina Pharmaceuticals Inc Endoxifeno para utilização no tratamento de cancro
GB2446780A (en) * 2007-02-22 2008-08-27 Glide Pharmaceutical Technolog An elongate parenteral injection body having an injection point of angle 10 to 40 degrees.
US7740619B2 (en) 2007-08-01 2010-06-22 Alcon Research, Ltd. Spring driven ophthalmic injection device with safety actuator lockout feature
US7629768B2 (en) 2007-08-03 2009-12-08 Alcon Research, Ltd. Easy cleaning C-shaped charging base
US8372036B2 (en) 2009-05-06 2013-02-12 Alcon Research, Ltd. Multi-layer heat assembly for a drug delivery device
GB0918450D0 (en) 2009-10-21 2009-12-09 Innovata Ltd Composition
US8177747B2 (en) 2009-12-22 2012-05-15 Alcon Research, Ltd. Method and apparatus for drug delivery
JP6062851B2 (ja) * 2010-04-30 2017-01-18 アロヴェイト・エルエルシー 口腔粘膜を介してアレルギーを減感作するための方法、物品及びキット
EP2397484A1 (de) * 2010-06-11 2011-12-21 Immunovo B.V. Trisaccharidderivate und ihre Verwendung als Adjuvantien
BR112014009866A2 (pt) 2011-10-25 2018-09-04 Onclave Therapeutics Limited formulações de anticorpos e métodos
KR101574760B1 (ko) 2013-11-13 2015-12-04 주식회사 엘지생활건강 흡수속도를 개선한 마이크로니들 시스템
WO2015093452A1 (ja) 2013-12-16 2015-06-25 武田薬品工業株式会社 マイクロニードル
US11273127B2 (en) 2014-05-06 2022-03-15 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses for thermally stable multi-targeted antigens
US10182939B2 (en) 2015-09-16 2019-01-22 Novartis Ag Hydraulic injector and methods for intra-ocular lens insertion
US11166968B2 (en) 2015-09-29 2021-11-09 Kimberly-Clark Worldwide, Inc. Synergistic composition for maintenance of healthy balance of microflora
KR102114993B1 (ko) * 2015-10-15 2020-05-25 주식회사 파이안에스테틱스 폴리펩타이드 및/또는 세포 배양 여액을 함유하는 수용성 스크럽 입자를 포함하는 화장제 조성물
GB2545880A (en) 2015-10-20 2017-07-05 Glide Pharmaceutical Tech Ltd Solid formulation
EP3419659A1 (de) 2016-02-23 2019-01-02 The Regents of the University of Colorado, A Body Corporate Zusammensetzungen und verfahren zur herstellung und verwendung thermostabiler immunogener formulierungen mit erhöhter kompatibilität der verwendung als impfstoffe gegen ein oder mehrere pathogene
KR102769558B1 (ko) 2017-02-28 2025-02-19 킴벌리-클라크 월드와이드, 인크. 미생물총의 건강한 균형을 유지하기 위한 상승적 조성물
IT201700101582A1 (it) * 2017-09-12 2019-03-12 Milano Politecnico Dispositivo per rilascio intraoculare
US20250011369A1 (en) * 2021-11-05 2025-01-09 Institute Of Process Engineering, Chinese Academy Of Sciences Cyclopeptide Glass and Pharmaceutical Composition Glass Containing Cyclopeptide
CN116942592B (zh) * 2023-05-05 2026-06-16 中国科学院过程工程研究所 一种水溶性生物分子玻璃微针及制备方法
WO2025205239A1 (ja) * 2024-03-28 2025-10-02 株式会社トクヤマ 組成物、乾燥試薬、及び組成物を保存する方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1080265B (de) * 1958-09-30 1960-04-21 Bayer Ag Verfahren zur Herstellung von oral anzuwendenden Arzneimittel-zubereitungen mit protrahierter Wirkung aus Wirkstoffen und Schutzstoffen
GB981372A (en) * 1960-05-04 1965-01-27 Pfizer Ltd Pharmaceutical formulations for oral administration to animals
JPH0779694B2 (ja) 1985-07-09 1995-08-30 カドラント バイオリソ−シズ リミテツド 蛋白質および同類品の保護
US4855326A (en) * 1987-04-20 1989-08-08 Fuisz Pharmaceutical Ltd. Rapidly dissoluble medicinal dosage unit and method of manufacture
JPH01288023A (ja) * 1988-05-16 1989-11-20 Nec Corp ミリ波構内無線通信方式
GB8903593D0 (en) 1989-02-16 1989-04-05 Pafra Ltd Storage of materials
AU5414990A (en) 1989-04-12 1990-11-05 Aberdeen University Slow release vitreous systems
US5079018A (en) * 1989-08-14 1992-01-07 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
GB9009390D0 (en) * 1990-04-26 1990-06-20 Smith Kline French Lab Pharmaceutical compositions
GB9010742D0 (en) 1990-05-14 1990-07-04 Quadrant Bioresources Ltd Stabilization of biological macromolecular substances
EP0615438B1 (de) * 1991-12-05 1996-07-24 Mallinckrodt Veterinary, Inc. Glasartige kohlenhydratenmatrize zur verabreichung von heilmitteln mit verzögerter wirkstoffabgabe
DK42093D0 (da) * 1993-04-07 1993-04-07 Bukh Meditec Administrationsmetode
TW404844B (en) * 1993-04-08 2000-09-11 Oxford Biosciences Ltd Needleless syringe

Also Published As

Publication number Publication date
CZ47697A3 (en) 1997-08-13
PL184068B1 (pl) 2002-08-30
FI970867A0 (fi) 1997-02-28
DE69531992D1 (de) 2003-11-27
JP2006056898A (ja) 2006-03-02
DK0773781T3 (da) 2004-02-16
NO971688D0 (no) 1997-04-11
HUT77777A (hu) 1998-08-28
ES2208687T3 (es) 2004-06-16
EP1138319A2 (de) 2001-10-04
JPH10503769A (ja) 1998-04-07
NO971688L (no) 1997-04-11
EP1138337A3 (de) 2003-03-26
WO1996003978A1 (en) 1996-02-15
SK27797A3 (en) 1997-08-06
EP1138319A3 (de) 2003-03-19
NZ290896A (en) 1997-04-24
SK283026B6 (sk) 2003-02-04
BG101278A (bg) 1997-12-30
EP1138337A2 (de) 2001-10-04
AU3185195A (en) 1996-03-04
EE9700062A (et) 1997-08-15
MX9701394A (es) 1998-03-31
CZ297431B6 (cs) 2006-12-13
FI970867L (fi) 1997-04-08
EP1516615A3 (de) 2007-10-31
AU688557B2 (en) 1998-03-12
EP0773781B1 (de) 2003-10-22
CN1152670C (zh) 2004-06-09
NO326966B1 (no) 2009-03-23
FI970867A7 (fi) 1997-04-08
PL318898A1 (en) 1997-07-21
EP0773781A1 (de) 1997-05-21
EE03593B1 (et) 2002-02-15
CA2197982A1 (en) 1996-02-15
PT773781E (pt) 2004-03-31
CN1204959A (zh) 1999-01-13
EP1516615A2 (de) 2005-03-23
DE69531992T2 (de) 2004-07-22
CA2197982C (en) 2010-03-23

Similar Documents

Publication Publication Date Title
DE69531992D1 (de) Feste verabreichungssysteme zur gesteuerten freisetzung von darin eingebauten molekülen sowie verfahren zu deren herstellung
EP0402031A3 (de) Injizierbare polymere Körper
DE59209658D1 (de) Pharmazeutische zusammensetzung zur wund-, narben- und keloidbehandlung
ATE54416T1 (de) Paramagnetische kontrastmittel fuer die anwendung in ''in vivo'' nmr-diagnostischen methoden und die herstellung davon.
NO971192L (no) Fremgangsmåter for avlevering av materialer inn i huden, og sammensetninger som blir anvendt
DE3853853D1 (de) Verabreichungsformen für Pharmaka.
AU2740595A (en) Transdermal drug delivery system
ES2046300T3 (es) Composicion para el tratamiento de la piel.
AU582887B2 (en) Surface treatment of soft contact lens
ATE143801T1 (de) Zusammensetzung zur kontrollierten abgabe eines wirkstoffes und verfahren zur herstellung derselben
ID17343A (id) Metode dan peralatan untuk penyembuhan tanaman
DE50014164D1 (de) Verfahren zur herstellung einer wasserunlöslichen amorphen retardmatrix
NO964915L (no) Transdermal avlevering av antiepileptiske legemidler
EP1106189A3 (de) Lichthärtender Gewebeklebstoff
WO1997009971A3 (en) High capacity, superabsorbent drug reservoirs for use in transdermal drug delivery systems
WO1996030028A3 (en) Method of mucociliary clearance in cystic fibrosis patients using alkylaryl polyether alcohol polymers
DE69526228D1 (de) Regioselektive sulfatierung
DE58904502D1 (de) Halterung fuer medizinische instrumente, insbesondere katheter, sowie verfahren zu deren herstellung.
KR20250101288A (ko) 약물전달용 마이크로니들 어레이 및 이를 포함하는 약물전달용 마이크로니들 패치
ATE117694T1 (de) Ketophosphamidglycoside, verfahren zu ihrer herstellung sowie ihre verwendung als pharmazeutische wirkstoffe.
SU1811202A1 (ru) Композиция уф-отверждения
WANG et al. The inhabitative effect of clonidine on the somatosensory evoked cerebral potential
FU et al. Feasibility of subarachnoid chromaffin cell allograft for terminal cancer pain
LU et al. Effect of cognitive intervention on the chronic prostatitis following sexually transmitted diseases
ZHOU et al. Causes of groin lymphatic fistula after transluminal ultrasonic angioplasty in the treatment of deep vein thrombosis of lower extremity

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0773781

Country of ref document: EP

EEFA Change of the company name
REN Ceased due to non-payment of the annual fee